Lewy Cisimcikli Demans Tedavisi

Gale SA, Acar D, Daffner KR. Dementia. Am J Med. 2018;131(10):1161-1169. doi:10.1016/j.amjmed.2018.01.022

Mueller C, Ballard C, Corbett A, et al. The prognosis of dementia with Lewy bodies. Lancet Neurol. 2017;16(5):390-398. doi:10.1016/S1474-4422(17)30074-1

Prasad S, Katta MR, Abhishek S, et al. Recent advances in Lewy body dementia: A comprehensive review. Dis Mon. 2023;69(5):101441. doi:10.1016/j.disamonth.2022.101441

Kane JPM, Surendranathan A, Bentley A, et al. Clinical prevalence of Lewy body dementia. Alzheimers Res Ther. 2018;10(1):19. Published 2018 Feb 15. doi:10.1186/s13195-018-0350-6

McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100. doi:10.1212/WNL.0000000000004058

Hyun CH, Yoon CY, Lee HJ, et al. LRRK2 as a Potential Genetic Modifier of Synucleinopathies: Interlacing the Two Major Genetic Factors of Parkinson's Disease. Exp Neurobiol. 2013;22(4):249-257. doi:10.5607/en.2013.22.4.249

Kasanuki K, Koga S, Dickson DW, et al. Mixed Alzheimer's and Lewy-related Pathology Can Cause Corticobasal Syndrome with Visual Hallucinations. Intern Med. 2019;58(12):1813. doi:10.2169/internalmedicine.1427-18

Gomperts SN. Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia. Continuum (Minneap Minn). 2016;22(2 Dementia):435-463. doi:10.1212/CON.0000000000000309

Romo-Gutiérrez D, Yescas P, López-López M, Boll MC. Factores genéticos de la demencia en la enfermedad de Parkinson (EP) [Genetic factors associated with dementia in Parkinson's disease (PD)]. Gac Med Mex. 2015;151(1):110-118

Tsuang D, Leverenz JB, Lopez OL, et al. APOE ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurol. 2013;70(2):223-228. doi:10.1001/jamaneurol.2013.600

Auning E, Rongve A, Fladby T, et al. Early and presenting symptoms of dementia with lewy bodies. Dement Geriatr Cogn Disord. 2011;32(3):202-208. doi:10.1159/000333072

Milán-Tomás Á, Fernández-Matarrubia M, Rodríguez-Oroz MC. Lewy Body Dementias: A Coin with Two Sides?. Behav Sci (Basel). 2021;11(7):94. Published 2021 Jun 22. doi:10.3390/bs11070094

McKeith IG, Ferman TJ, Thomas AJ, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94(17):743-755. doi:10.1212/WNL.0000000000009323

Killen A, Flynn D, De Brún A, et al. Support and information needs following a diagnosis of dementia with Lewy bodies. Int Psychogeriatr. 2016;28(3):495-501. doi:10.1017/S1041610215001362

Boot BP. Comprehensive treatment of dementia with Lewy bodies. Alzheimers Res Ther. 2015;7(1):45. Published 2015 May 29. doi:10.1186/s13195-015-0128-z

Watts KE, Storr NJ, Barr PG, Rajkumar AP. Systematic review of pharmacological interventions for people with Lewy body dementia. Aging Ment Health. 2023;27(2):203-216. doi:10.1080/13607863.2022.2032601

Edwards K, Royall D, Hershey L, et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Dement Geriatr Cogn Disord. 2007;23(6):401-405. doi:10.1159/000101512

Mori E, Ikeda M, Kosaka K; Donepezil-DLB Study Investigators. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol. 2012;72(1):41-52. doi:10.1002/ana.23557

Ikeda M, Mori E, Matsuo K, Nakagawa M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther. 2015;7(1):4. Published 2015 Feb 3. doi:10.1186/s13195-014-0083-0

Stinton C, McKeith I, Taylor JP, et al. Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. Am J Psychiatry. 2015;172(8):731-742. doi:10.1176/appi.ajp.2015.14121582

McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356(9247):2031-2036. doi:10.1016/S0140-6736(00)03399-7

Pakrasi S, Thomas A, Mosimann UP, et al. Cholinesterase inhibitors in advanced Dementia with Lewy bodies: increase or stop?. Int J Geriatr Psychiatry. 2006;21(8):719-721. doi:10.1002/gps.1547

Minett TS, Thomas A, Wilkinson LM, et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int J Geriatr Psychiatry. 2003;18(11):988-993. doi:10.1002/gps.995

Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613-618. doi:10.1016/S1474-4422(09)70146-2

Wesnes KA, Aarsland D, Ballard C, Londos E. Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry. 2015;30(1):46-54. doi:10.1002/gps.4109

Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969-977. doi:10.1016/S1474-4422(10)70194-0

Matsunaga S, Kishi T, Iwata N. Memantine for Lewy body disorders: systematic review and meta-analysis. Am J Geriatr Psychiatry. 2015;23(4):373-383. doi:10.1016/j.jagp.2013.11.007

Wang HF, Yu JT, Tang SW, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015;86(2):135-143. doi:10.1136/jnnp-2014-307659

Connors MH, Quinto L, McKeith I, et al. Non-pharmacological interventions for Lewy body dementia: a systematic review. Psychol Med. 2018;48(11):1749-1758. doi:10.1017/S0033291717003257

Satoh M, Ishikawa H, Meguro K, Kasuya M, Ishii H, Yamaguchi S. Improved visual hallucination by donepezil and occipital glucose metabolism in dementia with Lewy bodies: the Osaki-Tajiri project. Eur Neurol. 2010;64(6):337-344. doi:10.1159/000322121

Takahashi H, Yoshida K, Sugita T, Higuchi H, Shimizu T. Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(3):549-553. doi:10.1016/S0278-5846(03)00040-X

Cummings JL, Street J, Masterman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. Dement Geriatr Cogn Disord. 2002;13(2):67-73. doi:10.1159/000048636

Walker Z, Grace J, Overshot R, et al. Olanzapine in dementia with Lewy bodies: a clinical study. Int J Geriatr Psychiatry. 1999;14(6):459-466

Rothenberg KG, McRae SG, Dominguez-Colman LM, Shutes-David A, Tsuang DW. Pimavanserin Treatment for Psychosis in Patients with Dementia with Lewy Bodies: A Case Series. Am J Case Rep. 2023;24:e939806. Published 2023 Sep 30. doi:10.12659/AJCR.939806

Muller C, Merignac J, Moog C, Schorr B, Javelot H, Blanc F. Association pimavansérine et trazodone dans les troubles du comportementde la maladie à corps de Lewy sévère [Pimavanserin and trazodone combination in behavioral disorders in severe dementia with Lewy bodies]. Geriatr Psychol Neuropsychiatr Vieil. 2023;21(1):116-127. doi:10.1684/pnv.2023.1092

Jellinger KA. Depression in dementia with Lewy bodies: a critical update. J Neural Transm (Vienna). 2023;130(10):1207-1218. doi:10.1007/s00702-023-02669-8

Culo S, Mulsant BH, Rosen J, et al. Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial. Alzheimer Dis Assoc Disord. 2010;24(4):360-364. doi:10.1097/WAD.0b013e3181e6a4d7

Zhang W, Chen XY, Su SW, et al. Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials. Neurol Sci. 2016;37(1):57-65. doi:10.1007/s10072-015-2357-0

Treves N, Perlman A, Kolenberg Geron L, Asaly A, Matok I. Z-drugs and risk for falls and fractures in older adults-a systematic review and meta-analysis. Age Ageing. 2018;47(2):201-208. doi:10.1093/ageing/afx167

Iftikhar IH, Alghothani L, Trotti LM. Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis. Eur J Neurol. 2017;24(12):1446-1456. doi:10.1111/ene.13449

Terzaghi M, Arnaldi D, Rizzetti MC, et al. Analysis of video-polysomnographic sleep findings in dementia with Lewy bodies. Mov Disord. 2013;28(10):1416-1423. doi:10.1002/mds.25523

Ferman TJ, Boeve BF, Smith GE, et al. Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology. 2011;77(9):875-882. doi:10.1212/WNL.0b013e31822c9148

Jung Y, St Louis EK. Treatment of REM Sleep Behavior Disorder. Curr Treat Options Neurol. 2016;18(11):50. doi:10.1007/s11940-016-0433-2

Larsson V, Aarsland D, Ballard C, Minthon L, Londos E. The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. Int J Geriatr Psychiatry. 2010;25(10):1030-1038. doi:10.1002/gps.2506

Ferman TJ, Smith GE, Dickson DW, et al. Abnormal daytime sleepiness in dementia with Lewy bodies compared to Alzheimer's disease using the Multiple Sleep Latency Test. Alzheimers Res Ther. 2014;6(9):76. Published 2014 Dec 10. doi:10.1186/s13195-014-0076-z

Lapid MI, Kuntz KM, Mason SS, et al. Efficacy, Safety, and Tolerability of Armodafinil Therapy for Hypersomnia Associated with Dementia with Lewy Bodies: A Pilot Study. Dement Geriatr Cogn Disord. 2017;43(5-6):269-280. doi:10.1159/000471507

Devos D, Krystkowiak P, Clement F, et al. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease. J Neurol Neurosurg Psychiatry. 2007;78(5):470-475. doi:10.1136/jnnp.2006.100016

Moreau C, Delval A, Defebvre L, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial [published correction appears in Lancet Neurol. 2012 Aug;11(8):658] [published correction appears in Lancet Neurol. 2016 Mar;15(3):241] [published correction appears in Lancet Neurol. 2016 Mar;15(3):241. doi: 10.1016/S1474-4422(16)00009-0.]. Lancet Neurol. 2012;11(7):589-596. doi:10.1016/S1474-4422(12)70106-0

Kasanuki K, Iseki E, Nishida Y, et al. Effectiveness of ramelteon for treatment of visual hallucinations in dementia with Lewy bodies: a report of 4 cases. J Clin Psychopharmacol. 2013;33(4):581-583. doi:10.1097/JCP.0b013e318295fdf4

Fujishiro H. Nihon Ronen Igakkai Zasshi. 2012;49(5):622-626. doi:10.3143/geriatrics.49.622

Shen Y, Huang JY, Li J, Liu CF. Excessive Daytime Sleepiness in Parkinson's Disease: Clinical Implications and Management. Chin Med J (Engl). 2018;131(8):974-981. doi:10.4103/0366-6999.229889

Molloy S, McKeith IG, O'Brien JT, Burn DJ. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2005;76(9):1200-1203. doi:10.1136/jnnp.2004.052332

Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord. 2008;23(15):2248-2250. doi:10.1002/mds.22322

Matsunaga S, Kishi T, Iwata N. Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis. J Alzheimers Dis. 2017;56(4):1229-1239. doi:10.3233/JAD-161068

Odawara T, Shiozaki K, Togo T, Hirayasu Y. Administration of zonisamide in three cases of dementia with Lewy bodies. Psychiatry Clin Neurosci. 2010;64(3):327-329. doi:10.1111/j.1440-1819.2010.02075.x

Mendoza-Velásquez JJ, Flores-Vázquez JF, Barrón-Velázquez E, Sosa-Ortiz AL, Illigens BW, Siepmann T. Autonomic Dysfunction in α-Synucleinopathies. Front Neurol. 2019;10:363. Published 2019 Apr 12. doi:10.3389/fneur.2019.00363

Palma JA, Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord. 2018;33(3):372-390. doi:10.1002/mds.27344

Tateno F, Sakakibara R, Ogata T, et al. Lower urinary tract function in dementia with Lewy bodies (DLB). Mov Disord. 2015;30(3):411-415. doi:10.1002/mds.25985

Peyronnet B, Vurture G, Palma JA, et al. Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohort. Parkinsonism Relat Disord. 2018;57:22-26. doi:10.1016/j.parkreldis.2018.07.005

MacDonald S, Shah AS, Tousi B. Current Therapies and Drug Development Pipeline in Lewy Body Dementia: An Update. Drugs Aging. 2022;39(7):505-522. doi:10.1007/s40266-022-00939-w

Hebron M, Moussa CE. Two sides of the same coin: tyrosine kinase inhibition in cancer and neurodegeneration. Neural Regen Res. 2015;10(11):1767-1769. doi:10.4103/1673-5374.165320

Hebron ML, Lonskaya I, Moussa CE. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models [published correction appears in Hum Mol Genet. 2023 Jan 1;32(1):172-176. doi: 10.1093/hmg/ddac274.]. Hum Mol Genet. 2013;22(16):3315-3328. doi:10.1093/hmg/ddt192

Höllerhage M, Moebius C, Melms J, et al. Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells. Sci Rep. 2017;7(1):11469. Published 2017 Sep 13. doi:10.1038/s41598-017-11664-5

Khan SA, Khan S, Kausar H, et al. Insights into the management of Lewy body dementia: a scoping review. Ann Med Surg (Lond). 2024;86(2):930-942. Published 2024 Jan 3. doi:10.1097/MS9.0000000000001664

Silveira CRA, MacKinley J, Coleman K, et al. Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. BMC Neurol. 2019;19(1):20. Published 2019 Feb 9. doi:10.1186/s12883-019-1252-3

Telenius EW, Engedal K, Bergland A. Effect of a high-intensity exercise program on physical function and mental health in nursing home residents with dementia: an assessor blinded randomized controlled trial. PLoS One. 2015;10(5):e0126102. Published 2015 May 14. doi:10.1371/journal.pone.0126102

Tabak R, Aquije G, Fisher BE. Aerobic exercise to improve executive function in Parkinson disease: a case series. J Neurol Phys Ther. 2013;37(2):58-64. doi:10.1097/NPT.0b013e31829219bc

Hsu MH, Flowerdew R, Parker M, Fachner J, Odell-Miller H. Individual music therapy for managing neuropsychiatric symptoms for people with dementia and their carers: a cluster randomised controlled feasibility study. BMC Geriatr. 2015;15:84. Published 2015 Jul 18. doi:10.1186/s12877-015-0082-4

Ciro CA, Hershey LA, Garrison D. Enhanced task-oriented training in a person with dementia with Lewy bodies. Am J Occup Ther. 2013;67(5):556-563. doi:10.5014/ajot.2013.008227

Graff MJ, Vernooij-Dassen MJ, Thijssen M, Dekker J, Hoefnagels WH, Rikkert MG. Community based occupational therapy for patients with dementia and their care givers: randomised controlled trial. BMJ. 2006;333(7580):1196. doi:10.1136/bmj.39001.688843.BE

Kung, S., & Kevin O'Connor, M. (2002). ECT in Lewy Body dementia: A case report. Primary Care Companion to the Journal of Clinical Psychiatry, 4(4), 162

Rasmussen KG Jr, Russell JC, Kung S, Rummans TA, Rae-Stuart E, O'Connor MK. Electroconvulsive therapy for patients with major depression and probable Lewy body dementia. J ECT. 2003;19(2):103-109. doi:10.1097/00124509-200306000-00009

Yamaguchi Y, Matsuoka K, Ueda J et al. "The effect of electroconvulsive therapy on psychiatric symptoms of dementia with Lewy bodies." Journal of Neuropsychiatry and Clinical Neurosciences 28 (2016): e66.

Takahashi S, Mizukami K, Yasuno F, Asada T. Depression associated with dementia with Lewy bodies (DLB) and the effect of somatotherapy. Psychogeriatrics. 2009;9(2):56-61. doi:10.1111/j.1479-8301.2009.00292.x

Elder GJ, Colloby SJ, Firbank MJ, McKeith IG, Taylor JP. Consecutive sessions of transcranial direct current stimulation do not remediate visual hallucinations in Lewy body dementia: a randomised controlled trial. Alzheimers Res Ther. 2019;11(1):9. Published 2019 Jan 18. doi:10.1186/s13195-018-0465-9

Elder GJ, Firbank MJ, Kumar H, et al. Effects of transcranial direct current stimulation upon attention and visuoperceptual function in Lewy body dementia: a preliminary study. Int Psychogeriatr. 2016;28(2):341-347. doi:10.1017/S1041610215001180